%0 Journal Article
%T The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy
%A Hans Carl Hasselbalch
%A Mads Hald Andersen
%A Morten Orebo Holmstr£żm
%J Archive of "Oncoimmunology".
%D 2017
%R 10.1080/2162402X.2017.1358334
%X Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens
%K CD4 T-cells
%K calreticulin
%K Hematological cancer
%K JAK2
%K neoantigens
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674967/